Tarsons Products Limited (TARSONS)

Healthcare · Healthcare Equipment & Supplies · NSE · Updated 15 August 2026

By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings

₹360.3 ↑ 4.75% (1Y)

🎯 Key Takeaways

Tarsons Products Limited is in a strategic reinvestment phase, shifting from a mature, profitable business model to a growth-oriented structure with significant capital expenditure on new manufacturing facilities in Panchla and Amta. The company is prioritizing long-term export expansion and product diversification in labware and cell culture technologies, accepting short-term losses to capture future market share.
Revenue declined 3.6% QoQ to ₹96 in Q3FY25.
⚠️ Execution risk in scaling new facilities in Panchla and Amta on schedule and achieving projected revenue ramp-up from FY28 onward.

Market Cap

₹1,101

P/E Ratio

36.9

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About TARSONS 📊 Interactive Charts

📖 The Story

Tarsons Products Limited is in a strategic reinvestment phase, shifting from a mature, profitable business model to a growth-oriented structure with significant capital expenditure on new manufacturing facilities in Panchla and Amta. The company is prioritizing long-term export expansion and product diversification in labware and cell culture technologies, accepting short-term losses to capture future market share. This transition is reflected in declining margins and temporary profitability pressures, but underpinned by strong cash flow generation and management's confidence in scalable revenue ramp-up from FY28 onward.

📰 What's Happening

In Q1 FY27, Tarsons reported consolidated revenue of ₹110.2 crores, up 21% YoY, driven by domestic and export demand, though headline PAT turned negative at ₹1.4 crores due to accelerated depreciation and new facility setup costs. Cash PAT rose 18% YoY to ₹25.6 crores, highlighting robust cash conversion despite accounting losses. Management emphasized that revenue from the newly commissioned Panchla and Amta facilities is expected to materialize from FY28 and FY29, respectively, and reaffirmed ambitions to expand exports to 120 countries over 5–10 years. The company is also investing in automation and cell culture capabilities to drive future margin recovery and product mix improvement.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Q3FY22	Q4FY22	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25
Revenue	71	85	62	106	85	99	96
Operating Profit	36	47	26	34	22	34	30
OPM %	46.9%	52.2%	37.0%	28.6%	22.1%	25.5%	31.0%
Net Profit	21	29	10	10	4	10	5
EPS	₹4.14	₹5.69	₹1.87	₹1.94	₹0.75	₹1.93	₹0.99

The company has shown fluctuating profitability over the past few years, with operating margins peaking in Q3FY22 at 37% and declining to 22.1% in Q1FY25 before slightly recovering to 28.6% in Q4FY24. Revenue has grown steadily, peaking at ₹106 crores in Q4FY24, but profitability has been pressured by rising raw material costs and capitalization of new plant investments. Despite a net loss of ₹73 lakhs in Q1 FY2027, cash profit remained strong at ₹25.6 crores, indicating that operational cash generation remains resilient even as accounting losses rise due to depreciation and expansion costs. This suggests that the current losses are transitional and tied to strategic capex rather than structural weakness.

🔮 Management Outlook & What's Next

Management has provided a clear long-term growth roadmap, stating that revenue from new facilities in Panchla and Amta will begin flowing from FY28 and FY29, respectively. They expect export growth to accelerate, targeting penetration into 120 countries over the next decade, and are focusing on product diversification in labware and automation technologies. Margin recovery is anticipated as scale improves and fixed costs are absorbed, with no immediate guidance on profitability timelines but confidence in the sustainability of export-driven growth. The company is not providing short-term earnings guidance but is emphasizing capital efficiency and cash flow resilience during the investment phase.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Healthcare Equipment & Supplies

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Poly Medicure Limited	15,193	46.4	—	—	—
Fischer Medical Ventures Limited	2,261	59.0	—	—	—
Laxmi Dental Limited	1,105	57.2	—	—	—
Tarsons Products Limited	1,101	36.9	—	—	—
Fabtech Technologies Limited	681	—	—	—	—
Nureca Limited	260	-47.3	—	—	—

🔗 Peer Stock Analyses

POLYMED FISCHER LAXMIDENTL FABTECH NURECA

⚠️ Risk Factors

1. Execution risk in scaling new facilities in Panchla and Amta on schedule and achieving projected revenue ramp-up from FY28 onward. 2. Margin compression from rising raw material costs and accelerated depreciation during the capitalization phase, with no clear timeline for recovery. 3. Exposure to global export markets, which may be impacted by geopolitical, regulatory, or currency fluctuations, especially as the company targets expansion to 120 countries. 4. Regulatory and compliance risks related to new labor codes and ongoing review of excess director remuneration, which could lead to financial restatements or governance scrutiny.

📋 Recent Filings

🧠 Analyst's Read

Tarsons is undergoing a strategic pivot from a domestically focused, cyclical business to a globally oriented, innovation-driven growth model, requiring patience from investors as near-term profitability is sacrificed for long-term positioning. The company's cash flow resilience and export ambitions are positives, but the path to margin recovery and scalable revenue remains uncertain. Key near-term watchpoints include the timely commissioning of new facilities, management's ability to control input cost pressures, and early traction in international markets. Investors should monitor execution updates at the upcoming AGM and any forward-looking guidance on export milestones or product diversification progress.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on TARSONS

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-08-15.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when TARSONS files new disclosures

Track TARSONS filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track TARSONS — Free

Free account · 2 AI queries/day